Information Provided By: 
Fly News Breaks for June 9, 2017
NLNK
Jun 9, 2017 | 07:30 EDT
After Roche (RHBBY) returned GDC-0919 to NewLink (NLNK), SunTrust analyst Peter Lawson says that NewLink "is undervalued." The analyst says that Roche's decision won't affect NewLink's indoximod, which he thinks could generate $400M in peak sales. He adds that '919 has shown some signs of modest efficacy and could still produce value over the next year. The analyst cut his price target on NewLink to $19 from $30 but keeps a Buy rating on the stock.
News For NLNK From the Last 2 Days
There are no results for your query NLNK
